Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:10/20/2008

EAST SETAUKET, N.Y., Oct. 20 /PRNewswire-FirstCall/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT), announces the appointment of Mel Sorensen, M.D. to the company's Board of Directors.

Dr. Sorensen is currently Board Director, President and Chief Executive Officer of Ascenta Therapeutics. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development.

Trained as a medical oncologist, Dr. Sorensen has dedicated his career to clinical cancer research and cancer drug development. After completing his oncology fellowship at the Mayo Clinic, Rochester, MN in 1988, Dr. Sorensen spent seven years at the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). At CTEP, he managed collaborations between companies developing new anti-cancer agents and academic clinics and clinical cooperative groups. He had responsibility for over 40 research compounds.

Following NCI, Dr. Sorensen spent nearly eight years at large pharmaceutical companies in leadership roles in oncology clinical development and medical affairs. He established Bayer's first clinical oncology department and oversaw multiple clinical trials (Phase 1, 2 and 3) of novel agents. He subsequently joined GlaxoSmithKline (GSK) as Vice-President, Global Leader and North American Head of Clinical Development and Medical Affairs for Oncology, where he recruited a large team of physicians and scientists and led global clinical development of chemotherapeutic agents. While at GSK and Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, Nippon Kayaku, and Hoffmann-La Roche).

Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his leadership, in less than three years Ascenta was transformed from a 5-person start-up with a single preclinical program int
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
3. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
4. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
7. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
8. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
11. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Semiconductor industry leader ... Light-based Technologies (IYL 2015) visionary John Dudley were ... the international society for optics and photonics , last ... and Dudley along with other awards announced earlier this ... by James Harrington, during a gala banquet Wednesday evening ...
(Date:9/2/2014)... detailed studies of what happens on the surface of ... other applications. A group of researchers from Lund University ... form across a large number of vertical nanowires, known ... of a cell and its surroundings takes place through ... that holds the cell together and that largely comprises ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... Lumiphore, Inc., a,biotechnology leader in the ... use in high-value applications, announced,that it has ... Inc.,Redwood City, California to apply Lumiphore products ... Under the agreement, Biophor Diagnostics holds the ...
... Inc. (OTC,Bulletin Board: NZYM) announced today the appointment ... on October 1, 2008. Since May,2008, Dr. Farkas ... over 13 years, experience with amino acid derivatives, ... and supply chain,management at Bachem Corporation, Novartis AG ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer ... Chief Executive Officer,and Robert S. Brown, Chief Financial Officer, ... on October 6, 2008 at Le Parker,Meridien Hotel in ... Monday, October 6th at,2:30 p.m. ET. To listen to ...
Cached Biology Technology:Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Synthetech Announces New Director of Manufacturing 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:9/2/2014)... truth; everyone has a tipping point. We all want to ... benefit is great enough. Now, scientists have confirmed the area ... , The result was published online this week in ... honest, even if lying is beneficial," said Lusha Zhu, the ... Virginia Tech Carilion Research Institute , where she works with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... its prestigious Clinical and Translational Science Award (CTSA) ... the amount of $29 million over the next ... wireless technology and bioinformatics toward individualizing medicine. ... Health and The Scripps Research Institute in partnership ...
... 22, 2013 More accurate and precise assessment of ... a particular gene that are present in a genome, ... cancer and other diseases including autoimmune disorders. However, ... labor intensive, or prohibitively costly, diminishing their effectiveness in ...
... New research shows that in sub-Saharan Africa the virus responsible ... distances and the African buffalo are important natural reservoirs for ... online open-access journal of the American Society for Microbiology, sheds ... 2 emerged in sub-Saharan Africa and identifies patterns of spread ...
Cached Biology News:NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Bio-Rad's Droplet Digital PCR technology highlighted at ASHG Annual Meeting 2Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
...
Biology Products: